**SUPPLEMENT**

**Supplementary Authors and Affiliations**

**NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium Banner Authors:**

Namiko Abe1, Gonçalo Abecasis2, Francois Aguet3, Christine Albert4, Laura Almasy5, Alvaro Alonso6, Seth Ament7, Peter Anderson8, Pramod Anugu9, Deborah Applebaum-Bowden10, Kristin Ardlie3, Dan Arking11, Donna K Arnett12, Allison Ashley-Koch13, Stella Aslibekyan14, Tim Assimes15, Paul Auer16, Dimitrios Avramopoulos11, John Barnard17, Kathleen Barnes18, R Graham Barr19, Emily Barron-Casella11, Lucas Barwick20, Terri Beaty11, Gerald Beck21, Diane Becker22, Lewis Becker11, Rebecca Beer23, Amber Beitelshees7, Emelia Benjamin24, Takis Benos25, Marcos Bezerra26, Larry Bielak2, Joshua Bis27, Thomas Blackwell2, John Blangero28, Eric Boerwinkle29, Donald W Bowden30, Russell Bowler31, Jennifer Brody8, Ulrich Broeckel32, Jai Broome8, Karen Bunting1, Esteban Burchard33, Carlos Bustamante34, Erin Buth35, Brian Cade36, Jonathan Cardwell37, Vincent Carey38, Cara Carty39, Richard Casaburi40, James Casella11, Peter Castaldi41, Mark Chaffin3, Christy Chang7, Yi-Cheng Chang42, Daniel Chasman43, Sameer Chavan37, Bo-Juen Chen1, Wei-Min Chen44, Yii-Der Ida Chen45, Michael Cho38, Seung Hoan Choi3, Lee-Ming Chuang46, Mina Chung47, Ren-Hua Chung48, Clary Clish49, Suzy Comhair50, Matthew Conomos35, Elaine Cornell51, Adolfo Correa52, Carolyn Crandall40, James Crapo53, L Adrienne Cupples54, Joanne Curran55, Jeffrey Curtis2, Brian Custer56, Coleen Damcott7, Dawood Darbar57, Sayantan Das2, Sean David58, Colleen Davis8, Michelle Daya37, Mariza de Andrade59, Lisa de las Fuentes60, Michael DeBaun61, Ranjan Deka62,63, Dawn DeMeo38, Scott Devine7, Qing Duan64, Ravi Duggirala65, Jon Peter Durda51, Susan Dutcher66, Charles Eaton67, Lynette Ekunwe9, Adel El Boueiz68, Patrick Ellinor69, Leslie Emery8, Serpil Erzurum17, Charles Farber44, Tasha Fingerlin70, Matthew Flickinger2, Myriam Fornage29, Nora Franceschini71, Chris Frazar8, Mao Fu7, Stephanie M Fullerton8, Lucinda Fulton66, Stacey Gabriel3, Weiniu Gan23, Shanshan Gao37, Yan Gao9, Margery Gass72, Bruce Gelb73, Xiaoqi (Priscilla) Geng2, Mark Geraci74, Soren Germer1, Robert Gerszten75, Auyon Ghosh38, Richard Gibbs76, Chris Gignoux15, Mark Gladwin25, David Glahn77, Stephanie Gogarten8, Da-Wei Gong7, Harald Goring78, Sharon Graw18, Daniel Grine37, C Charles Gu66, Yue Guan7, Xiuqing Guo45, Namrata Gupta3, Jeff Haessler72, Michael Hall9, Daniel Harris7, Nicola L Hawley79,63, Jiang He80, Ben Heavner35, Susan Heckbert8, Ryan Hernandez81, David Herrington82, Craig Hersh83, Bertha Hidalgo14, James Hixson29, Brian Hobbs38, John Hokanson37, Elliott Hong7, Karin Hoth84, Chao (Agnes) Hsiung85, Yi-Jen Hung86, Haley Huston87, Chii Min Hwu88, Marguerite Ryan Irvin14, Rebecca Jackson89, Deepti Jain8, Cashell Jaquish23, Min A Jhun2, Jill Johnsen90, Andrew Johnson23, Craig Johnson8, Rich Johnston6, Kimberly Jones11, Hyun Min Kang91, Robert Kaplan92, Sharon Kardia2, Sekar Kathiresan3, Shannon Kelly56, Eimear Kenny73, Michael Kessler7, Alyna Khan8, Wonji Kim93, Greg Kinney37, Barbara Konkle87, Charles Kooperberg72, Holly Kramer94, Christoph Lange95, Ethan Lange37, Leslie Lange37, Cathy Laurie8, Cecelia Laurie8, Meryl LeBoff38, Jiwon Lee38, Seunggeun Shawn Lee2, Wen-Jane Lee88, Jonathon LeFaive2, David Levine8, Dan Levy23, Joshua Lewis7, Xiaohui Li45, Yun Li64, Henry Lin45, Honghuang Lin96, Keng Han Lin2, Xihong Lin97, Simin Liu98, Yongmei Liu99, Yu Liu100, Ruth J. F. Loos101, Steven Lubitz69, Kathryn Lunetta96, James Luo23, Michael Mahaney55, Barry Make11, Ani Manichaikul44, JoAnn Manson38, Lauren Margolin3, Lisa Martin102, Susan Mathai37, Rasika Mathias11, Susanne May35, Patrick McArdle7, Merry-Lynn McDonald14, Sean McFarland93, Stephen McGarvey67,63, Daniel McGoldrick8, Caitlin McHugh35, Hao Mei9, Luisa Mestroni18, Deborah A Meyers103, Julie Mikulla23, Nancy Min9, Mollie Minear23, Ryan L Minster25,63, Braxton D Mitchell7, Matt Moll41, May E Montasser7, Courtney Montgomery104, Arden Moscati73, Solomon Musani52, Stanford Mwasongwe9, Josyf C Mychaleckyj44, Girish Nadkarni73, Rakhi Naik11, Take Naseri105,63, Pradeep Natarajan106, Sergei Nekhai107, Sarah C Nelson35, Bonnie Neltner37, Deborah Nickerson8, Kari North64, Jeff O'Connell108, Tim O'Connor7, Heather Ochs-Balcom109, David T Paik110, Nicholette Palmer111, James Pankow112, George Papanicolaou23, Afshin Parsa7, Juan Manuel Peralta65, Marco Perez15, James Perry7, Ulrike Peters113, Patricia Peyser2, Lawrence S Phillips6, Toni Pollin7, Wendy Post114, Julia Powers Becker115, Meher Preethi Boorgula37, Michael Preuss73, Bruce Psaty8, Pankaj Qasba23, Dandi Qiao38, Zhaohui Qin6, Nicholas Rafaels116, Laura Raffield117, Vasan S Ramachandran96, D C Rao66, Laura Rasmussen-Torvik118, Aakrosh Ratan44, Susan Redline38, Robert Reed7, Elizabeth Regan53, Alex Reiner119, Muagututi‘a Sefuiva Reupena120, Ken Rice8, Stephen Rich44, Dan Roden121, Carolina Roselli3, Jerome Rotter45, Ingo Ruczinski11, Pamela Russell37, Sarah Ruuska87, Kathleen Ryan7, Ester Cerdeira Sabino122, Danish Saleheen19, Shabnam Salimi7, Steven Salzberg11, Kevin Sandow123, Vijay G Sankaran124, Christopher Scheller2, Ellen Schmidt2, Karen Schwander66, David Schwartz37, Frank Sciurba25, Christine Seidman125, Jonathan Seidman126, Vivien Sheehan127, Stephanie L Sherman128, Amol Shetty7, Aniket Shetty37, Wayne Hui-Heng Sheu88, M Benjamin Shoemaker129, Brian Silver130, Edwin Silverman38, Jennifer Smith2, Josh Smith8, Nicholas Smith131, Tanja Smith1, Sylvia Smoller92, Beverly Snively132, Michael Snyder15, Tamar Sofer38, Nona Sotoodehnia8, Adrienne M Stilp8, Garrett Storm37, Elizabeth Streeten7, Jessica Lasky Su38, Yun Ju Sung66, Jody Sylvia38, Adam Szpiro8, Carole Sztalryd7, Daniel Taliun2, Hua Tang133, Margaret Taub11, Kent D Taylor134, Matthew Taylor18, Simeon Taylor7, Marilyn Telen13, Timothy A Thornton8, Machiko Threlkeld135, Lesley Tinker72, David Tirschwell8, Sarah Tishkoff136, Hemant Tiwari137, Catherine Tong138, Russell Tracy139, Michael Tsai112, Dhananjay Vaidya11, David Van Den Berg140, Peter VandeHaar2, Scott Vrieze141, Tarik Walker37, Robert Wallace84, Avram Walts37, Fei Fei Wang8, Heming Wang142, Karol Watson40, Daniel E Weeks25,63, Bruce Weir8, Scott Weiss38, Lu-Chen Weng69, Jennifer Wessel143, Cristen Willer144, Kayleen Williams35, L Keoki Williams145, Carla Wilson38, James Wilson146, Quenna Wong8, Joseph Wu110, Huichun Xu7, Lisa Yanek11, Ivana Yang37, Rongze Yang7, Norann Zaghloul7, Maryam Zekavat3, Yingze Zhang147, Snow Xueyan Zhao53, Wei Zhao148, Degui Zhi29, Xiang Zhou2, Xiaofeng Zhu149, Michael Zody1, Sebastian Zoellner2

1New York Genome Center, New York, New York, 10013, US, 2University of Michigan, Ann Arbor, Michigan, 48109, US, 3Broad Institute, Cambridge, Massachusetts, 2142, US, 4Brigham & Women's Hospital, Cedars Sinai, Boston, Massachusetts, 2114, US, 5Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, US, 6Emory University, Atlanta, Georgia, 30322, US, 7University of Maryland, Baltimore, Maryland, 21201, US, 8University of Washington, Seattle, Washington, 98195, US, 9University of Mississippi, Jackson, Mississippi, 38677, US, 10National Institutes of Health, Bethesda, Maryland, 20892, US, 11Johns Hopkins University, Baltimore, Maryland, 21218, US, 12University of Kentucky, Lexington, Kentucky, 40506, US, 13Duke University, Durham, North Carolina, 27708, US, 14University of Alabama, Birmingham, Alabama, 35487, US, 15Stanford University, Stanford, California, 94305, US, 16University of Wisconsin Milwaukee, Milwaukee, Wisconsin, 53211, US, 17Cleveland Clinic, Cleveland, Ohio, 44195, US, 18University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, US, 19Columbia University, New York, New York, 10027, US, 20LTRC, The Emmes Corporation, Rockville, Maryland, 20850, US, 21Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, 44195, US, 22Medicine, Johns Hopkins University, Baltimore, Maryland, 21218, US, 23National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20892, US, 24Boston University School of Medicine, Boston University, Massachusetts General Hospital, Boston, Massachusetts, 2114, US, 25University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, US, 26Fundação de Hematologia e Hemoterapia de Pernambuco - Hemope, Recife, 52011-000, BR, 27Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, 98195, US, 28Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville, Texas, 78520, US, 29University of Texas Health at Houston, Houston, Texas, 77225, US, 30Department of Biochemistry, Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, US, 31National Jewish Health, National Jewish Health, Denver, Colorado, 80206, US, 32Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, US, 33University of California, San Francisco, San Francisco, California, 94143, US, 34Biomedical Data Science, Stanford University, Stanford, California, 94305, US, 35Biostatistics, University of Washington, Seattle, Washington, 98195, US, 36Brigham and Women's Hospital, Brigham & Women's Hospital, Boston, Massachusetts, 2115, US, 37University of Colorado at Denver, Denver, Colorado, 80204, US, 38Brigham & Women's Hospital, Boston, Massachusetts, 2115, US, 39Washington State University, Pullman, Washington, 99164, US, 40University of California, Los Angeles, Los Angeles, California, 90095, US, 41Medicine, Brigham & Women's Hospital, Boston, Massachusetts, 2115, US, 42National Taiwan University, Taipei, 10617, TW, 43Division of Preventive Medicine, Brigham & Women's Hospital, Boston, Massachusetts, 2215, US, 44University of Virginia, Charlottesville, Virginia, 22903, US, 45Lundquist Institute, Torrance, California, 90502, US, 46National Taiwan University Hospital, National Taiwan University, Taipei, 10617, TW, 47Cleveland Clinic, Cleveland Clinic, Cleveland, Ohio, 44195, US, 48National Health Research Institute Taiwan, Miaoli County, 350, TW, 49Metabolomics Platform, Broad Institute, Cambridge, Massachusetts, 2142, US, 50Immunity and Immunology, Cleveland Clinic, Cleveland, Ohio, 44195, US, 51University of Vermont, Burlington, Vermont, 5405, US, 52Medicine, University of Mississippi, Jackson, Mississippi, 38677, US, 53National Jewish Health, Denver, Colorado, 80206, US, 54Biostatistics, Boston University, Boston, Massachusetts, 2115, US, 55University of Texas Rio Grande Valley School of Medicine, Brownsville, Texas, 78520, US, 56Vitalant Research Institute, San Francisco, California, 94118, US, 57University of Illinois at Chicago, Chicago, Illinois, 60607, US, 58University of Chicago, Chicago, Illinois, 60637, US, 59Health Sciences Research, Mayo Clinic, Rochester, Minnesota, 55905, US, 60Department of Medicine, Cardiovascular Division, Washington University in St Louis, St. Louis, Missouri, 63110, US, 61Vanderbilt University, Nashville, Tennessee, 37235, US, 62University of Cincinnati, Cincinnati, Ohio, 45220, US, 63The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA) Group, 64University of North Carolina, Chapel Hill, North Carolina, 27599, US, 65University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas, 78539, US, 66Washington University in St Louis, St Louis, Missouri, 63130, US, 67Brown University, Providence, Rhode Island, 2912, US, 68Channing Division of Network Medicine, Harvard University, Cambridge, Massachusetts, 2138, US, 69Massachusetts General Hospital, Boston, Massachusetts, 2114, US, 70Center for Genes, Environment and Health, National Jewish Health, Denver, Colorado, 80206, US, 71Epidemiology, University of North Carolina, Chapel Hill, North Carolina, 27599, US, 72Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, US, 73Icahn School of Medicine at Mount Sinai, New York, New York, 10029, US, 74Medicine, Indiana University, Indianapolis, Indiana, 46202, US, 75Beth Israel Deaconess Medical Center, Boston, Massachusetts, 2215, US, 76Baylor College of Medicine Human Genome Sequencing Center, Houston, Texas, 77030, US, 77Yale University, New Haven, Connecticut, 6520, US, 78University of Texas Rio Grande Valley School of Medicine, San Antonio, Texas, 78229, US, 79Department of Chronic Disease Epidemiology, Yale University, New Haven, Connecticut, 6520, US, 80Tulane University, New Orleans, Louisiana, 70118, US, 81University of California, San Francisco, Montreal, H3A 0G4, CA, 82Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, US, 83Channing Division of Network Medicine, Brigham & Women's Hospital, Boston, Massachusetts, 2115, US, 84University of Iowa, Iowa City, Iowa, 52242, US, 85Institute of Population Health Sciences, NHRI, National Health Research Institute Taiwan, Miaoli County, 350, TW, 86Tri-Service General Hospital National Defense Medical Center, TW, 87Blood Works Northwest, Seattle, Washington, 98104, US, 88Taichung Veterans General Hospital Taiwan, Taichung City, 407, TW, 89Internal Medicine, DIvision of Endocrinology, Diabetes and Metabolism, Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, US, 90Blood Works Northwest, University of Washington, Seattle, Washington, 98104, US, 91Biostatistics, University of Michigan, Ann Arbor, Michigan, 48109, US, 92Albert Einstein College of Medicine, New York, New York, 10461, US, 93Harvard University, Cambridge, Massachusetts, 2138, US, 94Public Health Sciences, Loyola University, Maywood, Illinois, 60153, US, 95Biostats, Harvard School of Public Health, Boston, Massachusetts, 2115, US, 96Boston University, Boston, Massachusetts, 2215, US, 97Harvard School of Public Health, Boston, Massachusetts, 2115, US, 98Epidemiology and Medicine, Brown University, Providence, Rhode Island, 2912, US, 99Cardiology, Duke University, Durham, North Carolina, 27708, US, 100Cardiovascular Institute, Stanford University, Stanford, California, 94305, US, 101The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, US, 102George Washington University, Washington, District of Columbia, 20052, US, 103University of Arizona, Tucson, Arizona, 85721, US, 104Genes and Human Disease, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, US, 105Ministry of Health, Government of Samoa, Apia, WS, 106Broad Institute, Harvard University, Massachusetts General Hospital, Boston, Massachusetts, 2114, US, 107Howard University, Washington, District of Columbia, 20059, US, 108University of Maryland, Baltimore, Maryland, 21201, US, 109University at Buffalo, Buffalo, New York, 14260, US, 110Stanford Cardiovascular Institute, Stanford University, Stanford, California, 94305, US, 111Biochemistry, Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, US, 112University of Minnesota, Minneapolis, Minnesota, 55455, US, 113Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, 98195, US, 114Cardiology/Medicine, Johns Hopkins University, Baltimore, Maryland, 21218, US, 115Medicine, University of Colorado at Denver, Denver, Colorado, 80204, US, 116University of Colorado at Denver, Denver, Colorado, 80045, US, 117Genetics, University of North Carolina, Chapel Hill, North Carolina, 27599, US, 118Northwestern University, Chicago, Illinois, 60208, US, 119Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, 98109, US, 120Lutia I Puava Ae Mapu I Fagalele, Apia, WS, 121Medicine, Pharmacology, Biomedicla Informatics, Vanderbilt University, Nashville, Tennessee, 37235, US, 122Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, 1310000, BR, 123TGPS, Lundquist Institute, Torrance, California, 90502, US, 124Division of Hematology/Oncology, Broad Institute, Harvard University, Cambridge, Massachusetts, 2142, US, 125Genetics, Harvard Medical School, Boston, Massachusetts, 2115, US, 126Harvard Medical School, Boston, Massachusetts, 2115, US, 127Pediatrics, Baylor College of Medicine, Houston, Texas, 77030, US, 128Human Genetics, Emory University, Atlanta, Georgia, 30322, US, 129Medicine/Cardiology, Vanderbilt University, Nashville, Tennessee, 37235, US, 130UMass Memorial Medical Center, Worcester, Massachusetts, 1655, US, 131Epidemiology, University of Washington, Seattle, Washington, 98195, US, 132Biostatistical Sciences, Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, US, 133Genetics, Stanford University, Stanford, California, 94305, US, 134Institute for Translational Genomics and Populations Sciences, Lundquist Institute, Torrance, California, 90502, US, 135University of Washington, Department of Genome Sciences, University of Washington, Seattle, Washington, 98195, US, 136Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, US, 137Biostatistics, University of Alabama, Birmingham, Alabama, 35487, US, 138Department of Biostatistics, University of Washington, Seattle, Washington, 98195, US, 139Pathology & Laboratory Medicine, University of Vermont, Burlington, Vermont, 5405, US, 140USC Methylation Characterization Center, University of Southern California, University of Southern California, California, 90033, US, 141University of Colorado at Boulder, University of Minnesota, Boulder, Colorado, 80309, US, 142Brigham & Women's Hospital, Partners.org, Boston, Massachusetts, 2115, US, 143Epidemiology, Indiana University, Indianapolis, Indiana, 46202, US, 144Internal Medicine, University of Michigan, Ann Arbor, Michigan, 48109, US, 145Henry Ford Health System, Detroit, Michigan, 48202, US, 146Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, 2215, US, 147Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, US, 148Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, 48109, US, 149Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, 44106, US

**Supplemental Figures**

**Figure S1.** Manhattan and QQ plots for pooled single variant analysis with fasting glucose and fasting insulin in TOPMed. The Manhattan plots show the -log10 *P-values* for the variants across the chromosomal positions with a threshold of 5×10-8 plotted in red; the QQ-plots show the observed versus expected -log10 *P-values*. The plots are stratified by common (MAF>=0.05) and rare (MAF<0.05) variants for all variants with MAC>=20.

1. Fasting Glucose, MAF>=0.05Chart

   Description automatically generatedChart, line chart

   Description automatically generated
2. Fasting Glucose, MAF<0.05A picture containing chart

   Description automatically generatedChart, line chart

   Description automatically generated
3. Fasting Insulin, MAF>=0.05Chart, bar chart

   Description automatically generatedChart, line chart

   Description automatically generated
4. Fasting Insulin, MAF<0.05A picture containing chart

   Description automatically generatedChart, line chart

   Description automatically generated

**Figure S2.** Regional locus plots of the twelve loci significant in pooled analysis with stepwise conditional analysis. The loci associated with FG (a-b. *MTNR1B,* b. *G6PC2,* c. *GCK,* d. *GCKR,* e. *FOX2A,* f. *SLC30A8,* g. *APOB,* h. *TCF7L2,* i. *ADCY5*) and FI (j. *GCKR,* k. *PTPRT,* l. *ROBO1*). The linkage disequilibrium is given with respect to the index variant and was calculated in the TOPMed analysis sample. Plots denoted by rsID and MarkerID (Chromosome:Position(Hg38):Reference-Allele:Alternative-Allele).

1. *MTNR1B*, rs10830963, 11:92975544:C:G

Chart, waterfall chart

Description automatically generated

1. *MTNR1B*, rs73560545, 11:92884161:G:A

Chart

Description automatically generated

1. *G6PC2*, rs560887, 2:168906638:T:C

Timeline

Description automatically generated

1. *G6PC2*, rs540524, 2:168900420:A:G

Timeline

Description automatically generated

1. *G6PC2*, rs2232326, 2:168907981:T:C

Timeline

Description automatically generated

1. *GCK*, rs1799884, 7:44189469:C:T

Chart

Description automatically generated

1. *GCKR*, rs1260326, 2:27508073:T:C

Timeline

Description automatically generated

1. *FOXA2*, rs3833331, 20:22581688:A:AG

A picture containing timeline

Description automatically generated

1. *SLC30A8*, rs35859536, 8:117179236:C:T

Chart

Description automatically generated

1. *SLC30A8*, rs542965166, 8:117258547:C:T

Chart, timeline

Description automatically generated

1. *APOB*, rs478588, 2:21074277:A:G

A picture containing timeline

Description automatically generated

1. *TCF7L2*, rs7903146, 10:112998590:C:T

Chart

Description automatically generated

1. *ADCY5*, rs72964564, 3:123335923:A:C

A picture containing chart

Description automatically generated

1. *GCKR*, rs1260326, 2:27508073:T:C

A picture containing timeline

Description automatically generated

1. *PTPRT*, rs185250851, 20:42752773:G:ATimeline

   Description automatically generated
2. *PTPRT*, rs78618809, 20:43230137:C:T

Chart

Description automatically generated

1. *ROBO1*, rs539973028, 3:79812347:C:A

Chart, waterfall chart

Description automatically generated

**Figure S3.** Manhattan plots for pooled region-based rare variant aggregate analysis with fasting glucose (a-d) and fasting insulin (e-h) in TOPMed. The Manhattan plot shows the -log10 *P-values* for the variant sets plotted at the starting chromosomal positions, using the burden test and the SKAT test.

1. Fasting Glucose, SKAT (1,1)

A screenshot of a cell phone

Description automatically generated

1. Fasting Glucose, SKAT (1,25)

A close up of a logo

Description automatically generated

1. Fasting Glucose, Burden (1,1)

A picture containing building, fence

Description automatically generated

1. Fasting Glucose, Burden (1,25)

A close up of a fence

Description automatically generated

1. Fasting Insulin, SKAT (1,1)

A close up of a building

Description automatically generated

1. Fasting Insulin, SKAT (1,25)

A close up of a logo

Description automatically generated

1. Fasting Insulin, Burden (1,1)

A picture containing building, fence

Description automatically generated

1. Fasting Insulin, Burden (1,25)

A close up of a fence

Description automatically generated

**Figure S4.** Plot of associations with related traits of identified loci in single variant analysis. The plot shows a black indicator for traits that have been previously identified as associated; see also **Table S12**.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **FG** | **FI** | **HbA1c** | **T2D** | **BMI** | **WHR** | **HOMA-B** |
| *MTNR1B* | **** |  | **** | **** | **** |  | **** |
| *G6PC2* | **** |  | **** |  |  |  | **** |
| *GCK* | **** |  | **** | **** |  |  | **** |
| *GCKR* | **** | **** |  | **** | **** |  |  |
| *FOXA2* | **** |  |  | **** |  |  |  |
| *SLC30A8* | **** |  | **** | **** | **** |  |  |
| *APOB* |  |  |  |  |  |  |  |
| *TCF7L2* | **** | **** | **** | **** | **** | **** |  |
| *ADCY5* | **** |  | **** | **** | **** | **** | **** |
| *PTPRT* |  |  |  |  | **** | **** |  |
| *ROBO1* |  |  |  |  | **** | **** |  |

Abbreviations: FG, fasting glucose; FI, fasting insulin; HbA1c, hemoglobin A1c; T2D, Type 2 Diabetes; BMI, body mass index; WHR, waist-hip ratio; HOMA-B, homeostatic model assessment of beta-cell function.

**Supplemental Tables**

**Table S1. Description of TOPMed studies included in glycemic trait analysis**

**Table S2. Demographic characteristics of cohorts included in fasting glucose analysis**

**Table S3. Demographic characteristics of cohorts included in fasting insulin analysis**

**Table S4. Haplotype analysis of the *G6PC2* locus**

**Table S5. Number of rare variant sets by phenotype and set-type**

**Table S6. Results of log Fasting Insulin gene-centric rare variant aggregate tests**

**Table S7. Results of Fasting Glucose gene-centric rare variant aggregate tests**

**Table S8. Results of log Fasting Insulin genetic-regions rare variant aggregate tests**

**Table S9. Results of Fasting Glucose genetic-regions rare variant aggregate tests**

**Table S10. References for previous identification of variants in this study**

**Table S11. Reference for previous identification of gene regions in this study**

**Table S12. Lookups in related traits of identified loci in TOPMed projects**

**Table S13. Validation lookups of novel signals in METSIM cohorts**

**Table S14. Validation lookups of novel signals in the UKBB**

**Table S15. Validation lookups of novel signals in the Samoan cohort**

**Supplemental Subjects and Methods**

**Whole Genome Sequencing**

Whole genome sequencing of blood samples for all participants included deep coverage (>30x on average) sequencing from blood samples provided by the NHLBI TOPMed program. Sequencing was performed across six centers (Broad Institute of MIT and Harvard, Northwest Genomics Center, New York Genome Center, Illumina Genomic Services, Macrogen, and Baylor College of Medicine Human Genome Sequencing Center) as previously described1. The TOPMed Informatics Research Center at the University of Michigan performed data harmonization and joint variant discovery and genotype calling, requiring DNA sample contamination below 3% and at least 95% of the genome with at least 10x coverage. Freeze 5b was aligned to GRCh38 reads from the 1000 Genomes Project reference sequences2. The samples were further processed by a centralized pipeline by the TOPMed Data Coordinating Center at the University of Washington, where further quality control and sample identity resolution were performed, including sex and relatedness concordance and selection of variants with missingness <5% and QUAL>127. After processing, Freeze 5b contained 54,508 samples with 438 million single nucleotide variants (SNVs) and 33 million short insertion-deletion variants.

Population structure principal components were calculated across all Freeze 5b TOPMed participants using PC-AiR; a genetic relatedness matrix was calculated across all Freeze 5b TOPMed participants using PC-Relate accounting for population structure. Race/ethnicity was determined by self-report from each study.

**Phenotype Harmonization**

Phenotype harmonization proceeded following a protocol defined by the TOPMed Diabetes Working Group for participating TOPMed studies. Duplicated individuals were excluded following the TOPMed Diabetes Working Group protocol. Within a study, monozygotic twins were retained and the duplicate to be kept was chosen based on verification of cohort characteristics, including proper cohort sequencing center designation, and then by highest call rate. Across studies, duplicates were selected by removing missing trait data, prioritizing population-based cohorts, and retaining individual records with the longest follow-up period. All study participants provided informed consent and each study was approved by their respective institutional review boards.

Glycemic traits (fasting glucose (FG) and fasting insulin (FI)) were analyzed for individuals who did not have diabetes at the time of glycemic trait measurement. This subset was defined as those not taking anti-diabetes medication, with fasting glucose <7mmol/l and/or HbA1c<6.5%. For individuals with multiple blood draws, the earliest exam or most complete exam was used. Age, sex, and BMI covariates were reported at the time of glycemic trait measurement. Fasting was defined to be at least 8 hours without food or drink; measurements from blood were converted to plasma values using a 1.13 correction factor3. The units for glucose are mmol/l; units for insulin are pmol/l. Fasting insulin was natural log-transformed prior to analysis in order to address non-normality.

**Study Sample and Power**

The present analysis included 23,211 (FI) and 26,807 (FG) individuals from the NHLBI TOPMed program. The cohorts included consist of participants of self-reported African American (FI n=6,803; FG n=7,174), East Asian (FI n=572; FG n=2,217), European (FI n=13,281; FG n=14,513), Hispanic/Latinx (FI n=1,641; FG n=1,989), and Samoan (FI n=914; FG n=914) race/ethnicity. Our analysis of fasting insulin included 14 cohorts and fasting glucose included 15 cohorts. The sample is predominantly of European race/ethnicity (FI 57.2%; FG 54.1%) and female (FI 66.5%; FG 65.2%); full cohort descriptions are given in **Tables S2-3**.

We performed a post-hoc power calculation to evaluate the power to detect genetic signal at the genome-wide threshold for statistical significance of 5x10-8. Given the study sample size, this analysis was powered to detect 0.54%-4.21% and 0.57-4.21% percent variation in glycemic trait explained by a genotype in race/ethnicity-specific analyses for FG and FI, respectively. The pooled study including all samples was powered to detect 0.16% and 0.17% percent variation in glycemic trait explained by a genotype for FG and FI, respectively.

**Single Variant Analysis**

We performed single variant analysis in Freeze 5b of TOPMed using race/ethnicity-specific and pooled approaches. We tested 64,675,008 variants for associations with FG and 58,759,883 with FI in both pooled and race/ethnicity-specific analyses, and restricted analysis to variants with minor allele count >= 20. We used linear mixed effects models and adjusted for age, age squared, sex, body mass index, study-race/ethnicity, with heterogeneous variance permitted across study-race/ethnicity groups and empirical kinship for relatedness and population structure. Models were fit using GENetic Estimation and Inference in Structured samples (GENESIS)4 in the Analysis Commons cloud-computing platform5. Fasting glucose and natural log transformed fasting insulin were used as outcomes in separate models. The genome-wide threshold for statistical significance was defined to be 5x10-8.

Stepwise conditional analysis was performed at each identified locus, defined to be a 500 kb region centered on the most significant variant, in order to identify distinct signals. This analysis proceeded by first including the most significant variant as a covariate, and repeating until no variants were associated with the phenotype with p-value <1x10-5. For each distinct signal, a final model was run conditioning on the set of other distinct signals; we report these potentially distinct signals.

Towards fine-mapping the identified loci, we generated 95% credible sets to investigate likely causal variants (LocalZoom). For each locus, we calculated Bayes factors for all variants from their single variant p-value; p-values were taken from conditional analyses on all other identified variants at the locus where multiple distinct signals were identified in the stepwise conditional analysis. We calculated posterior probability of association (PP) of each variant as the proportion contributed to the summation of all BFs in the region. The variants were sorted by descending PP, indicating decreasing probability that the variant is truly associated with the glycemic trait. The 95% credible set was constructed by including variants, starting with the highest PPA, until their cumulative PPA exceeded 0.95.

**Rare Variant Analysis**

We performed gene-based and genetic region aggregate testing to identify sets of rare variants associated with fasting glucose and log-transformed fasting insulin. We first fit a heteroscedastic linear mixed model for fasting glucose and log-transformed fasting insulin. Both traits were adjusted for age, age2, sex, body mass index (BMI), study-race/ethnicity group indicators, and ten population structure principal components. A variance component was included for the empirically derived sparse kinship matrix and residual variances were permitted to be different for study-race/ethnicity groups to account for family relatedness, population structure, and study-race/ethnicity differences.

The heteroscedastic linear mixed model was used to perform variant set analyses for rare variants with MAF < 1%. Sets were defined by genetic regions and gene-centric categories. Genetic regions allowed the complete analysis of the genome, particularly non-coding regions that have not been previously captured by arrays. The regional analysis used 2kb sliding windows to scan the genome with 1kb skip length. The gene-centric analysis examined all protein-coding genes in Ensembl using functionally determined masks to aggregate variants together by coding and noncoding annotations. Coding annotations were used to define three SNV filters categorized by GENCODE based on consequence: (a) putative loss of function (stop gain, stop loss, splicing), (b) missense, and (c) synonymous variants. Leveraging the whole genome sequencing, we used non-coding annotations to test sets of variants that are not protein coding. We constructed masks (d) characterized as promoters given they were within +/- 3kb of a transcription start site with CAGE signal overlay, or (e) characterized as enhancers given they were identified by GeneHancer with CAGE signal overlay.

The burden test and SKAT were used for testing the association of the rare variant sets and FG and FI. In these approaches, a weight based on the MAF can be used to upweight rarer variants. We considered two common weighting schemes based on , where and or and .

Statistical significance was defined for each glycemic trait, separately for gene-centric and genetic region analysis. For gene-centric analysis, a threshold was defined by a Bonferroni-corrected significance threshold of , correcting for all five masks and all protein-coding genes when considering the minimum p-value across the burden and SKAT tests (**Table S5**). The threshold for the genetic region analysis was determined given the total number of 2kb sliding windows tested, yielding a Bonferroni-corrected threshold of . We report sets that include variant(s) with effective minor allele count greater than five and that are not exclusively composed of singletons; complete results based on the significance threshold are provided in **Tables S6-9**.

**Haplotype Analysis**

We performed haplotype analysis for variants associated with fasting glucose. This analysis considered a set of 18,071 unrelated individuals, identified by PC-AiR6 by the TOPMed Program with a threshold of third degree relatives. We performed regression of fasting glucose on haplotype using a two-step EM algorithm on the unphased genotypes, as implemented in the haplo.stats R package7. The posterior probabilities of haplotypes were computed for variants in the *G6PC2* gene; the variants were included based on the variants included in a previous *G6PC2* haplotype analysis, variants driving the *G6PC2* missense set signal, and distinct *G6PC2* signals from the single variant analysis. The association was adjusted for age, age2, sex, body mass index, study-race/ethnicity, and ten population structure principal components.

**Annotation**

In order to characterize the functional impact of associated variants, we assembled functional annotations from multiple publicly available databases. We considered annotations from the Diabetes Epigenome Atlas, FAVOR, and GTEx projects. From the Diabetes Epigenome Atlas, we obtained chromatin states from four tissues relevant to glycemic traits: adipose, islet, liver, and muscle. These were available from two experiments, Parker lab ChromHMM 13-state model under accession TSTSR679993 & AMP-T2D ChromHMM 18-state model under accession TSTSR043890. We also report annotation PCs from the FAVOR database8, which are summaries of individual functional annotations across functional categories including conservation, epigenetics, local nucleotide diversity, mutation density, protein function, proximity to TSS/TSE, proximity to coding, and transcription factor binding. The individual annotations contributing to the aPCs are previously described9. Annotation PCs are calculated at the variant level and reported as PHRED-scaled scores derived from the first PC from the category’s PCA, providing the interpretation that variants with scores greater than 10 are in the top 10% of category across all TOPMed variants. We obtained tissue-specific signals from the GTEx project (Version 8) to assess colocalization with gene expression at signal variants and those highly linked to signal variants. We reported eQTLs in the following tissues, reported for their importance in glycemic phenotypes: adipose subcutaneous, adipose visceral, muscle skeletal, and pancreas.

**Replication**

We sought to replicate our findings in the METSIM study10, using data from 10,058 individuals with fasting glucose, fasting insulin, and TOPMed-imputed genotypes. EMMAX was used to test for associations with fasting glucose or log-transformed fasting insulin at the variants reported in **Table 1** with age, age2, and BMI as covariates and kinship; sex was not included as a covariate as the study is all males.

We additionally performed replication analysis in a sample from the UK Biobank. A sample of 12,854 European ancestry individuals from the UK Biobank with fasting glucose was selected from all individuals with fasting glucose measurement, excluding individuals with diabetes (Data-field 2443), on diabetes medication (Data-field 6177/6153), or with fasting time less than 8 hours (Data-field 74). Glucose values were taken from variable 30740. The model included age (Data-field 21022), age2, sex (Data-field 31), BMI (Data-field 21001) and ten population structure PCs. Association models were run using Scalable and Accurate Implementation of GEneralized mixed model (SAIGE)11 to analyze UKBB phenotype data and the imputed chip genetic data.

We also performed replication analysis of the Samoan-specific association of rs117592405 with fasting insulin in a cohort of 1,401 Samoans without WGS from the Samoan Study. rs117592405 was imputed using a Samoan-specific reference panel that was developed from the WGS of 1,284 Samoans as part of TOPMed. R version 3.6.0 was used to replicate the association with fasting insulin in individuals without a previous diabetes diagnosis or diabetes medication use. Age, age2, BMI, and sex were included in the model.

**Supplemental Results**

*MTNR1B*

The primary association at the *MTNR1B* locus, intronic variant rs10830963*,* has been identified in multiple populations to increase fasting glucose (**Table S11**), and has posterior probability of one in the present study. This signal has been characterized as amongst the strongest signal for insulin secretion12. The variant has previously been demonstrated to be expressed in in pancreatic islets; it is near the top 10% of variants genome-wide for APC-epigenetics. The variant is in a weakly transcribed chromatin state in islets, which is further supported by both the distance to TSS/TSE and transcription factor aPCs where it is in the top 5-10% genome-wide. The variant has been identified as a metabolite QTL for glucose13; 14. The variant has further been associated with risk of type 2 diabetes, demonstrating that this trait has further influence on the clinical disease, but with mechanisms still under study.

*TCF7L2*

This locus has known associations with glycemic traits, and this variant has been identified in previous study to be significantly associated with fasting glucose and type 2 diabetes (**Table S11**, ClinVar). It is an intronic variant between exons 4 and 5, and while commonly observed across most ancestries it has low frequency in East Asian populations in TOPMed and gNOMAD. This variant is in an active enhancer state in both adipose tissue and islets, designated by GeneHancer and SuperEnhancer, and has a high score for the annotation PC measuring distance to coding. The variant has been annotated to be in accessible chromatin in pancreatic beta cell, islet of Langerhans, and pancreatic alpha cell and to be targeting TCF7L2 by gene prediction annotation derived from chromatin loops in islet of Langerhans. The functionality of this variant has been further studied previously15; 16, with gene’s role hypothesized to be mediating the variant’s association with islet-specific traits17.

*ADCY5*

The common, intronic variant rs72964564 had the highest posterior probability at this locus (PP = 0.37); the common variant rs11708067 had posterior probability of 0.34 and has previously been identified as the lead variant at this locus in multiple studies. These variants are highly linked (R2= 0.86 in the present study sample), and have both been designated as GeneHancer and SuperEnhancer variants. Their chromatin states differ, as the previously identified lead variant rs11708067 is in active enhancer 2 and weak enhancer states in islets and skeletal muscle, respectively; rs72964564 is in weakly transcribed states for these tissues. However, rs72964564 is in an active enhancer state for adipose whereas this is in strong transcription for rs72964564. The previously identified rs11708067 is highly conserved, as evidenced by aPC-Conservation score of 20.3, and also is amongst the top 10% for both aPC-Epigenetics and aPC-Transcription Factors.  
  
We identified a single-variant signal at the *GCK* locus that has been previously associated with FG and related trait HbA1c18. The rs1799884 variant, which lies 2KB upstream of the gene near the transcription start site and was identified by GeneHancer, significantly increased expression in thyroid tissue of *GCK* and *YKT6* in GTEx. It is in an active enhancer 2 state in islets, while weakly transcribed in liver. It was reported to be in an accessible chromatin state in DGA in numerous tissues, including liver, pancreatic alpha and beta cells, pancreatic progenitors, body of pancreas, pancreatic acinar cell, and islet of Langerhans. It correspondingly has multiple chromatin interaction target genes in tissues including muscle and adipose cells. It has been identified as a metabolite QTL for glucose. Its functional annotations indicate that it is conserved (aPC-Conservation 11.7, LINSIGHT 13.0) and likely deleterious (CADD 11.7.)

The *GCKR* locus was the only locus significant in both of our FG and FI analyses; the lead variant, rs1260326, has been associated with a large number of traits including glycemic and metabolic. This missense variant in exon 15 of *GCKR* is associated with higher FG and FI and its active functionality is suggested by its relatively high aPC-Epigenetics and aPC-Transcription Factor values. It is an eQTL with multiple genes, in multiple tissues, including influencing *NRBP1* expression in many tissues. It has been associated with multiple proteins as a pQTL, most relevantly with insulin19. This variant is in an active enhancer 1 region in liver, whereas all other significant variants were in less active states. This liver-specificity is understood as this gene regulates glucose storage and disposal in the liver20. This variant impacts multiple traits by controlling the *GCK* binding interface21.

*FOXA2*, a glycemic trait-associated locus, was observed to have one FG-associated signal. The variant, rs3833331, is in the 3’ UTR of the gene and is classified as a CAGE promoter, GeneHancer, and SuperEnhancer. This variant (PP=0.78) is moderately linked to previously identified *FOXA2* lead variants (rs6048205 upstream near TSS, rs6048216 ncRNA\_intronic, rs1209523 downstream near TSE) which each have posterior probability less than 1x10-4 and are not in the 12-variant 95% credible set; our primary variant rs3833331 is suggested to be the same signal based on conditional analysis. The variant rs3833331 is frequent in African individuals, while it is relatively low frequency in European and Hispanic race/ethnicities. It is active only in islets, as it is in an active TSS state for both pancreas and islet of Langerhans. This variant significantly decreased the expression of both *LINC01384* and *FOXA2* in thyroid; *FOXA2* regulates gene expression ‘for glucose sensing in pancreatic beta cells22.’

Our analysis identified a significant signal at the *APOB* locus, which has been associated with many lipids traits. Some lipids traits have been studied for their pleiotropic effects with glycemic traits; *APOB* has not been associated with glycemic traits in previous studies. The FG-associated intergenic variant, rs478588, is common in all populations. The lead variant has posterior probability of 0.27, and is moderately linked with all variants in the credible set. This variant is primary in quiescent regions across tissues but is weakly transcribed in liver. Previous studies have been inconclusive as to the pleiotropic effects of *APOB* with respect to glycemic traits, and this signal was not replicated in METSIM and UKBB.

Our single-variant analysis identified a secondary variant associated with *MTNR1B*, having conditioned on the known primary signal, rs10830963, which has a well-replicated association with FG. This secondary, intronic variant, *rs73560545,* had a posterior probability of 0.21 in the 95% credible set having conditioned on the primary variant; *rs73560545* is highly linked (r2>0.98) to the two other variants with a posterior probability >0.1 (rs57569860 PP=0.18; rs73560556 PP=0.18). Each of these three variants are upstream of the primary signal and have an estimated FG lowering effect, in contrast to the primary signal. The secondary variant *rs73560545* is in a quiescent low chromatin state for islets, whereas the two linked variants are in weak transcription states in islets, and has aPC-Epigenetics and aPC-Distance to TSS/TSE scores near the top 10% genome-wide (PHRED: 9.6 and 9.7, respectively). We sought to replicate this signal in external datasets, but did not observe significance in METSIM or UKBB (**Supplemental Subjects and Methods; Tables S13-14**).

**Additional References**

1. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Gagliano Taliun, S.A., Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2020). Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature Accepted.

2. Regier, A.A., Farjoun, Y., Larson, D.E., Krasheninina, O., Kang, H.M., Howrigan, D.P., Chen, B.J., Kher, M., Banks, E., Ames, D.C., et al. (2018). Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. Nat Commun 9, 4038.

3. Haeckel, R., Brinck, U., Colic, D., Janka, H.U., Puntmann, I., Schneider, J., and Viebrock, C. (2002). Comparability of blood glucose concentrations measured in different sample systems for detecting glucose intolerance. Clin Chem 48, 936-939.

4. Gogarten, S.M., Sofer, T., Chen, H., Yu, C., Brody, J.A., Thornton, T.A., Rice, K.M., and Conomos, M.P. (2019). Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics 35, 5346-5348.

5. Brody, J.A., Morrison, A.C., Bis, J.C., O'Connell, J.R., Brown, M.R., Huffman, J.E., Ames, D.C., Carroll, A., Conomos, M.P., Gabriel, S., et al. (2017). Analysis commons, a team approach to discovery in a big-data environment for genetic epidemiology. Nat Genet 49, 1560-1563.

6. Conomos, M.P., Miller, M.B., and Thornton, T.A. (2015). Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. Genet Epidemiol 39, 276-293.

7. Lake, S.L., Lyon, H., Tantisira, K., Silverman, E.K., Weiss, S.T., Laird, N.M., and Schaid, D.J. (2003). Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55, 56-65.

8. (2020). The NHGRI Genome Sequencing Program (GSP). Functional Annotation of Variants - Online Resource (FAVOR) Server In., p <http://favor.genohub.org>.

9. Li, X., Li, Z., Zhou, H., Gaynor, S.M., Liu, Y., Chen, H., Sun, R., Dey, R., Arnett, D.K., Aslibekyan, S., et al. (2020). Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nat Genet 52, 969-983.

10. Laakso, M., Kuusisto, J., Stancakova, A., Kuulasmaa, T., Pajukanta, P., Lusis, A.J., Collins, F.S., Mohlke, K.L., and Boehnke, M. (2017). The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res 58, 481-493.

11. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J., VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet 50, 1335-1341.

12. Bonnefond, A., and Froguel, P. (2017). The case for too little melatonin signalling in increased diabetes risk. Diabetologia 60, 823-825.

13. Kettunen, J., Tukiainen, T., Sarin, A.P., Ortega-Alonso, A., Tikkanen, E., Lyytikainen, L.P., Kangas, A.J., Soininen, P., Wurtz, P., Silander, K., et al. (2012). Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 44, 269-276.

14. Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A.J., Lyytikainen, L.P., Pirinen, M., et al. (2016). Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun 7, 11122.

15. Pang, D.X., Smith, A.J., and Humphries, S.E. (2013). Functional analysis of TCF7L2 genetic variants associated with type 2 diabetes. Nutr Metab Cardiovasc Dis 23, 550-556.

16. Mondal, A.K., Das, S.K., Baldini, G., Chu, W.S., Sharma, N.K., Hackney, O.G., Zhao, J., Grant, S.F., and Elbein, S.C. (2010). Genotype and tissue-specific effects on alternative splicing of the transcription factor 7-like 2 gene in humans. J Clin Endocrinol Metab 95, 1450-1457.

17. Miguel-Escalada, I., Bonas-Guarch, S., Cebola, I., Ponsa-Cobas, J., Mendieta-Esteban, J., Atla, G., Javierre, B.M., Rolando, D.M.Y., Farabella, I., Morgan, C.C., et al. (2019). Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet 51, 1137-1148.

18. Sarnowski, C., Leong, A., Raffield, L.M., Wu, P., de Vries, P.S., DiCorpo, D., Guo, X., Xu, H., Liu, Y., Zheng, X., et al. (2019). Impact of Rare and Common Genetic Variants on Diabetes Diagnosis by Hemoglobin A1c in Multi-Ancestry Cohorts: The Trans-Omics for Precision Medicine Program. Am J Hum Genet 105, 706-718.

19. Strawbridge, R.J., Dupuis, J., Prokopenko, I., Barker, A., Ahlqvist, E., Rybin, D., Petrie, J.R., Travers, M.E., Bouatia-Naji, N., Dimas, A.S., et al. (2011). Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 60, 2624-2634.

20. Beer, N.L., Tribble, N.D., McCulloch, L.J., Roos, C., Johnson, P.R., Orho-Melander, M., and Gloyn, A.L. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18, 4081-4088.

21. Zelent, B., Raimondo, A., Barrett, A., Buettger, C.W., Chen, P., Gloyn, A.L., and Matschinsky, F.M. (2014). Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J 459, 551-564.

22. Wang, H., Gauthier, B.R., Hagenfeldt-Johansson, K.A., Iezzi, M., and Wollheim, C.B. (2002). Foxa2 (HNF3beta ) controls multiple genes implicated in metabolism-secretion coupling of glucose-induced insulin release. J Biol Chem 277, 17564-17570.